New book by Larry Connors Click here Improve your trading - See how
NOVARTIS IN TALKS WITH MUMBAI TRADERS TO SOLVE BOYCOTT ISSUE
NEW DELHI - Drug firm Novartis India, which is facing a threat from traders' association in Mumbai to boycott its products, on Friday said it is in talks with the traders to resolve the issue.
"Novartis India Ltd is in dialogue with the trade associations on the issue," a company spokesperson said in response to a written query.
INDIA'S SUVEN LIFE SCIENCES COMPLETES TRAIL OF ALZHEIMER'S DRUG
MUMBAI - Suven Life Sciences (BSE: 530239) on Thursday said it had completed the phase I clinical trial in Switzerland for its new molecule - SUVN 502 - used in the treatment of Alzheimer's disease.
"The company has completed its Phase I multiple ascending dose study of SUVN-502 in healthy volunteers," Suven Life Sciences said in a filing to the Bombay Stock Exchange.
JAPAN'S TAKEDA MOVING TO PHASE II TRIALS ON ANOTHER CANCER DRUG
TOKYO - Takeda Pharmaceutical Co. (TSE:4502) expects to move into phase II clinical trials within the year on a cancer drug candidate developed by U.S. bioventure Millennium Pharmaceuticals Inc., which Takeda acquired in 2008.
MLN4924 is being developed as both oral and injection preparations and is now in phase I trials in the U.S. It works by inhibiting NEDD8, an enzyme essential to cancer cell proliferation.
TOYOTA TSUSHO TEAMS WITH CANADIAN FIRM ON DRUG DEVELOPMENT
TOKYO - The Toyota Tsusho Corp. (TSE:8015) announced Friday plans to enter the drug development support business in partnership with Canadian chemical contract research company ChemRoutes Corp.
Under an agreement it has signed to be ChemRoutes' general sales agent in Japan, trading house Toyota Tsusho will sell ChemRoutes compounds to Japanese pharmaceutical manufacturers.
JAPAN'S SEVEN & I, AIN PHARMACIEZ TO FORM DRUG JV IN MAY
TOKYO - japan's Seven & i Holdings Co. (TSE:3382) announced Thursday that it will create a joint venture with Ain Pharmaciez Inc. (TSE:9627) to run a drugstore chain and develop generic drugs.
The two sides have reached a basic agreement to establish the new firm in late May. Seven & i will take a 10 per cent stake, with group firms Ito-Yokado Co. and Seven-Eleven Japan Co. acquiring interests of 50 per cent and 10 per cent respectively. The remainder of the firm will belong to Ain Pharmaciez.
AUST FOOD CO PULLS NUTS FROM STORES ON SALMONELLA SCARE
SYDNEY - An Australian company is pulling its range of pistachio nut-based products off store shelves, after a salmonella scare hit its American supplier.
South Australia-based Nocelle Foods is conducting a voluntary recall of its nut and yoghurt products. A company spokesman said it was a precautionary move and no Australians had fallen ill.
FITCH DOWNGRADES WOCKHARDT INDIA RATINGS
MUMBAI - Credit rating agency Fitch on Wednesday downgraded ratings of the long-term debt programmes of Wockhardt Ltd (India) (BSE: 532300) to a level indicating an extremely weak credit profile.
The downgrade from rating B (ind) to C (ind) follows the public information showing that the company has stopped making its scheduled debt payments pending finalisation of its corporate debt restructuring plan, Fitch said in a statement.
S KOREAN GOVT BANS IMPORTS OF TALCUM POWDER CONTAINING ASBESTOS
SEOUL - The government decided on Thursday to ban imports of talcum powder that contains asbestos, a cancer-causing substance, following a recent scandal involving the carcinogen detected in baby powder products.
The Korea Food & Drug Administration banned the sale of baby powder products made by eight manufacturers last week after their products were found to contain asbestos, a mineral that can cause serious illnesses, including lung cancer, when inhaled.
DAIICHI SANKYO ANTI-CLOTTING DRUG MAKES WORLD DEBUT IN U.K.
TOKYO - The Daiichi Sankyo Co. (TSE:4568) said Wednesday that its Efient anti-clotting agent had been launched in the U.K., the drug's first market.
Positioned as Daiichi Sankyo's next blockbuster, Efient was discovered with Ube Industries Ltd. (TSE:4208).
KYOTO UNIV LICENSES STEM CELL PATENTS TO 2 BIOTECH FIRMS
OSAKA - Kyoto University's affiliated stem cell patent management firm has reached licensing agreements with two Japanese biotech start-ups.
Shinya Yamanaka, a professor in the university's department of stem cell biology, succeeded in generating stem cells from human skin in 2007.
KOREAN RECALL FOR DRUGS SUSPECTED OF ASBESTOS CONTAMINATION
SEOUL - South Korea's health authorities on Thursday decided to ban the sale of 1,222 medicine products and ordered their recall as they are suspected to be contaminated with asbestos.
The products include those made by such high-profile drug manufacturers as Dong-A Pharm. and Hanmi Pharm. (KSE:008930), according to the Korea Food and Drug Administration. A total of 120 drug makers are subject to the regulatory measure.
INDIA'S STRIDES ARCOLAB GETS USFDA NOD FOR HIV TABLETS
MUMBAI - Indian pharmaceutical firm Strides Arcolab (BSE:532531) on Wednesday said it has received nod from US administration for dose combination of Lamivudine and Stavudine tablets used to treat adults and children who are infected with HIV.
It has received approval from the United States Food and Drug Administration for one new drug application for fixed dose combination of Lamivudine and Stavudine tablets, Strides Arcolab said in a filing to the Bombay Stock Exchange.
US OFFERS VIETNAM $US7.3MLN TO COMBAT BIRD FLU
HANOI - The US Government will provide $US7.3 million through the UN Food and Agriculture Organisation (FAO) to Vietnam to implement two projects on preventing and combating bird flu.
The documents relating to the projects were signed by Deputy Minister of Agriculture and Rural Development Diep Kinh Tan and FAO Representative Andrew Speedy, in Hanoi on April 8.
CHINA'S HEALTH-CARE REFORM TO REQUIRE SOFTWARE WORTH US$1.5 MLN
BEIJING - China's 850 billion yuan (US$124 billion) health-care reform blueprints call for at least US$1.5 billion in orders for the global software industry, IBM's Chinese development laboratory said.
The American computer giant said that according to the health-care reform more than 1,000 Chinese hospitals would each spend at least US$1.5 million in establishing electronic medical records.
NOVARTIS INDIA WEBSITE IS HACKED
NEW DELHI - The website of the Indian arm of Swiss drug major Novartis was hacked on Tuesday.
When contacted, a company spokesperson confirmed the report to PTI, saying "we will make all efforts to ensure that the website is up and running at the earliest."
GUNZE'S NEW ARTIFICIAL HEART MEMBRANE DISSOLVES AFTER SURGERY
TOKYO - Japan's Gunze Ltd. (TSE:3002) has developed a biodegradable artificial pericardium material that will completely dissolve some three months after heart surgery.
The pericardium, or the membrane sac that encloses the heart, must be cut open to access the heart for surgery.
JAPAN'S ASAHI KASEI TO MARKET HEART ASSIST DEVICE OVERSEAS
TOKYO - Asahi Kasei Corp. (TSE:3407) and Nagano Prefecture-based medical equipment maker Misuzu & Sun Medical Holdings Co. announced Tuesday an agreement to cooperate on overseas development and marketing of an implantable heart assist device.
Asahi Kasei has invested US$7.5 million, or roughly 750 million yen, to take a 60 per cent stake in Misuzu subsidiary Evaheart Medical USA Inc. Asahi Kasei will also shoulder the cost of U.S. clinical trials, which is expected to total billions of yen.
BANGLADESH TEAM LEAVES FOR LIBYA TO SEEK BIZ OPPORTUNITIES
DHAKA - A 10-member high profile business team is leaving here for Libya on Wednesday to tap business opportunities in manpower, garment and medicine.
During its weeklong tour, the delegation, led by Enayet Karim, CEO of Dhaka International Exhibition Company Limited (DIEC) and President of Global Economic Forum, will meet different chamber of commerce and trade associations.
INDIAN DRUG MAKERS WELCOME TO JOIN 'PATENT POOL' PROG: GSK
NEW DELHI - Global drug major GlaxoSmithKline has said Indian drug makers and research firms can join its 'patent pool' programme aimed at developing low cost drugs for 16 neglected tropical diseases.
The company recently launched the 'patent pool' programme aimed at developing drugs at a cheaper price for 16 neglected tropical diseases (NTDs) in poor countries.
AUSTRALIANS TO PAY LESS FOR DRUGS UNDER BUDGET PLAN: PAPER
SYDNEY - Australian consumers would pay less for 100 common prescription medicines under a budget plan to cut the price paid to drug companies.
The plan would result in savings of hundreds of millions of dollars a year and lower the price of some common medicines, including blood pressure, cholesterol and arthritis drugs, The Daily Telegraph reported on Wednesday.
ANALYSIS: CHINA'S HEALTH-CARE REFORM PLAN POSITIVE ON MEDICAL INDUSTRY
BEIJING - China's health-care reform blueprint, unveiled on Monday, by the State Council, or the cabinet, is much in line with industry expectation.
And the follow-up action plan for the three years from 2009 to 2011, published Tuesday, along with the pending release of the catalogue of basic medicines and measures relating to unified guiding price for basic medicines will cast concrete impact on health-care companies and the pharmaceutical industry as a whole, analysts hold.
CHINA TO TACKLE RURAL MEDICAL STAFF SHORTAGES UNDER NEW PLAN
BEIJING - China will deal with shortages of medical staff in underdeveloped rural areas under medical system reform plans published Tuesday.
In the reform plan for 2009-2011, China pledged to offer about 1.9 million training sessions for village and township medical clinics and urban community medical institutions over the next three years.
CHINA UNVEILS PLAN FOR UNIVERSAL ACCESS TO BASIC HEALTH CARE
BEIJING - China unveiled a three-year action plan on health care reform Tuesday, which it said would lay a solid foundation for equitable and universal access to essential health care for all in China.
Under the 850 billion yuan (US$124 billion) plan for 2009 to 2011, the government promised universal access to basic health insurance, introduction of an essential drug system, improved primary health care facilities, equitable access to basic public health services and pilot reform of state-run hospitals.
CHINA TO SET UP HEALTH CLINICS IN EVERY VILLAGE WITHIN 3 YEARS
BEIJING - China will set up at least one clinic in every village within three years to improve health care at grassroots level, according to an implementation plan for medical reform released by the State Council on Tuesday.
The government will also support the construction of 2,000 hospitals at the county level to guarantee that each county has a hospital that meets the national standard, the three-year plan (2009-2011) said. More township hospitals and clinics will be built or expanded in 2009.
PHILIPPINES' BFAD CONDUCTS CONTAMINATION TESTS ON IMPORTED NUTS
MANILA - After it ordered a recall of imported pistachio nuts and pistachio products from the United States for reported salmonella contamination, the Bureau of Food and Drugs (BFAD) said Tuesday it is also conducting tests on similar products imported from other countries.
BFAD director Leticia Barbara Gutierrez said in a radio interview they have also gathered pistachio products from other countries which will be tested with other products imported from the US.
TURKMEN STUDENTS DISCUSS SAVE MOTHERHOOD AT USAID CONFERENCE
ASHGABAT - Turkmenistan hosted an interactive student conference on safe motherhood in the Scientific-Clinical Center of Maternal and Child Health by the Turkmen State Medical Institute with support of the ZdravPlus project of the USAID on April 4.
Representatives of the Ministry of Health and Medical Industry, Health Information Center, international organization, teachers and students of medical school, and staff of the Clinical Center for Maternal and Child Health attended the conference.
TURKMENISTAN HOSTS WORLD HEALTH DAY CONFERENCE
ASHGABAT - `People's health - basis of the life' is the motto of a conference being held at Magtymguly Turkmen State University to mark World Health Day which is celebrated by our country together with world community on April 7.
The public organisations, the Ministry of Education and administration of Magtymguly Turkmen State University organized the forum, reports Turkmen State News Agency (TDH).
INDIA'S WOCKHARDT TO SELL MINORITY STAKE IN HOSPITAL BIZ
NEW DELHI - Debt-ridden Wockhardt (BSE:532300) today said it will sell only a minority stake in its Indian healthcare chain, Wockhardt Hospitals.
"We have expressed interests to sell a minority stake in the hospital chain to an investor," a Wockhardt Spokesperson said but declined to give further details about the quantum and valuation of the stake sale.
JAPAN'S OTSUKA PHARMA EXTENDS BRISTOL-MYERS SQUIBB DEAL TO '15
TOKYO - Otsuka Pharmaceutical Co. said Monday that it has extended its contract with U.S. drugmaker Bristol-Myers Squibb Co. for the aripiprazole anti-psychotic and will receive a lump-sum payment of 400 million dollars.
The agreement, which covers joint development and marketing in the U.S., was extended for two years and five months and now runs through April 2015. The two firms originally signed the deal in 1999, and U.S. sales of the anti-psychotic began in 2002.
U.S.- AFFILIATED MEDICAL DEVICE MAKERS FORM ASSOCIATION IN JAPAN
TOKYO - The local arms of 62 U.S. medical device companies have formed an association to promote their mutual interests in Japan.
The American Medical Devices and Diagnostics Manufacturer's Association (AMDD) will lobby on behalf of its members to speed up the process in Japan by which new medical devices become approved for marketing.
CHINA TO PAY FOR US$4 MLN HOSPITAL IN N. VIETNAM
LAO CAI - A Chinese-invested hospital, worth 70 billion VND (US$3.92 million), will be built in the northern mountainous province of Lao Cai.
The 500-bed hospital is a joint venture between the Lao Cai Medical Centre and a hospital of the Chinese province of Yunnan.
AGILENT LAUNCHES INDIA INNOVATION INITIATIVE
NEW DELHI - Communication and life sciences analyst Agilent Technologies on Monday announced the launch of the India Innovation Initiative (i3) in collaboration with the Department of Science and Technology and industry body CII.
"The programme has the objective of creating an eco system for conducive growth by promoting innovators and facilitating commercialisation of such project, which could a new idea, technology or software," Agilent Technology President and Country General Manger (India ) Venkatesh Valluri told reporters here.
AUSTRALIAN DRUG CO DERMATECH RECALLING CONTAMINATED SKIN OINTMENT
CANBERRA - Australian medicines company Dermatech is recalling batches of skin ointment contaminated with a chemical linked to tumours in animals.
The recall follows consultations between the nation's medicines regulator - the Therapeutic Goods Administration (TGA) - and Sydney-based Dermatech Laboratories Pty Ltd.
KEBUN RIMAU TO BE MALAYSIA'S FIRST NONI FRUIT-BASED POWDER PRODUCER
TAWAU (Malaysia) - Kebun Rimau Sdn Bhd will emerge as the first Noni powder producer in the country when mass production begins before year-end.
Kebun Rimau General Manager K. Arunagirinathan said facilities to produce the noni fruit-based powder has been set up within the integrated plantation area and production trial was in progress.
S KOREAN RESEARCHERS DEVELOPING ARTIFICIAL EARDRUMS, BONE FROM SILK
SEOUL - South Korean researchers are close to developing artificial eardrums and bone from silk proteins that could spur local production of the material, a state-run laboratory said Tuesday.
The National Academy of Agricultural Science (NAAS) under the Rural Development Administration said development of silk-based eardrums is almost complete, with the first prototype to be unveiled within the year. The eardrum will be the first of its kind in the world since most products on the market are made from plastic and silicon.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
